Master in Medicinal and Biopharmaceutical Chemistry

Target Identification and Diagnostics



Learning outcomes

After completion of the course, students will be expected to:

  • have an understanding of the concept of target identification and deconvolution in the context of drug discovery and development,
  • be aware that target identification can be approached by direct chemoproteomic methods, genetic interactions or computational inference,
  • be able to rationally design chemical probes for (photo)affinity-based and activity-based protein profiling,
  • know and understand the basic mass spectrometry methodologies used for proteomic studies and target identification,
  • have acquired knowledge and skills on the theoretical and applied concepts of radiopharmaceuticals for diagnostics,
  • be able to rationally design chemical tools for Single Photon Emission Tomography (SPECT) and Positron Emission Tomography (PET).


Chemogenomics in target and drug discovery; chemical libraries, chemical space and biological space;
Bioorthogonal chemistry in the context of probe design and synthesis; molecular probes for real-time imaging in live cells;
Identification of catalytic proteins in proteomes and activity-based probes (activity-based protein profiling); Identification of non-catalytic proteins in proteomes and (photo)affinity-based probes (affinity-based protein profiling); proteomics and target identification.

Detection methods and interaction of radiation and particles with matter; the nuclear techniques (SPECT/PET) for molecular imaging; design and development of radiopharmaceuticals; (radio)chemistry of metal and non-metal elements relevant to targeting, bioconjugation and pharmacokinetics modulation.